It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]
European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction
Data Indicate Administering Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Intravenously Improves Cardiac Function Following an AMI
ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI” at the European Society of Cardiology (ESC) Congress.
Paper Co-Author Dr. Michael Lipinski, Interventional Cardiologist at MedStar Washington Hospital Center, presents the study that was designed in collaboration with Drs. Dror Luger, Research Scientist at Washington Hospital Center and Stephen Epstein, Director, Translational and Vascular Biology Research at MedStar Heart and Vascular Institute, Chair of CardioCell’s Scientific Advisory Board and Member of CardioCell’s Heart Failure Advisory Board. [Read more…]
Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more
This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will address the regulation of stem cells within the United States. [Read more…]
Enrollment Complete for CardioCell’s Phase IIa Chronic Heart Failure Trial Utilizing Ischemia-Tolerant MSCs
In major news released today, CardioCell, LLC, annnounced that it had completed enrollment for its Phase IIa chronic heart failure (HF) clinical trial.
The Phase IIa study protocol delivers ischemia-tolerant mesenchymal stem cells (itMSCs) via intravenous infusion to participants with non-ischemic cardiomyopathy. CardioCell’s itMSCs are exclusively licensed from its parent company, Stemedica.
Complete details for the clinical trials can be viewed at: http://clinicaltrials.gov/ct2/show/NCT02123706.
To learn more, view the full press release issued by CardioCell, LLC, below. [Read more…]
